40 related articles for article (PubMed ID: 12010799)
1. Factor VIII binding affects the mechanical unraveling of the A2 domain of von Willebrand factor.
Cao W; Cao W; Zhang W; Zheng XL; Zhang XF
J Thromb Haemost; 2020 Sep; 18(9):2169-2176. PubMed ID: 32544272
[TBL] [Abstract][Full Text] [Related]
2. circ_0001274 Competitively Binds miR-143-3p to Upregulate VWF Expression to Improve Acute Traumatic Coagulopathy.
Luo Y; Liu S; Li Q; Zhang Y; Fu Y; Yang N; Zeng J; Tan T; Hu J; Li F; Zeng L; Zhang W; Liao Z; Wu K; Hu Y; Luo Z; Peng J
Oxid Med Cell Longev; 2023; 2023():9650323. PubMed ID: 36760352
[TBL] [Abstract][Full Text] [Related]
3. Defective VWF secretion due to expression of MYH9-RD E1841K mutant in endothelial cells disrupts hemostasis.
Cao Y; Sun Y; Deng Y; Wei G; Liu J; Jin S; Dong C; Kang X; Huo Y; Zhang J; Luo J
Blood Adv; 2022 Aug; 6(15):4537-4552. PubMed ID: 35764499
[TBL] [Abstract][Full Text] [Related]
4. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.
Takeyama M; Nogami K; Kobayashi R; Ogiwara K; Taniguchi A; Nakanishi Y; Inagaki Y; Tanaka Y; Shima M
Int J Hematol; 2018 Aug; 108(2):199-202. PubMed ID: 29383626
[TBL] [Abstract][Full Text] [Related]
5. Identification of extant vertebrate
Grant MA; Beeler DL; Spokes KC; Chen J; Dharaneeswaran H; Sciuto TE; Dvorak AM; Interlandi G; Lopez JA; Aird WC
Blood; 2017 Dec; 130(23):2548-2558. PubMed ID: 28899852
[TBL] [Abstract][Full Text] [Related]
6. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Shi Q; Schroeder JA; Kuether EL; Montgomery RR
J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
[TBL] [Abstract][Full Text] [Related]
7. A new recombinant factor VIII: from genetics to clinical use.
Santagostino E
Drug Des Devel Ther; 2014; 8():2507-15. PubMed ID: 25548513
[TBL] [Abstract][Full Text] [Related]
8. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.
Stockschlaeder M; Schneppenheim R; Budde U
Blood Coagul Fibrinolysis; 2014 Apr; 25(3):206-16. PubMed ID: 24448155
[TBL] [Abstract][Full Text] [Related]
9. Blood Clotting Factor VIII: From Evolution to Therapy.
Orlova NA; Kovnir SV; Vorobiev II; Gabibov AG; Vorobiev AI
Acta Naturae; 2013 Apr; 5(2):19-39. PubMed ID: 23819034
[TBL] [Abstract][Full Text] [Related]
10. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes.
Dasgupta S; Navarrete AM; Bayry J; Delignat S; Wootla B; André S; Christophe O; Nascimbeni M; Jacquemin M; Martinez-Pomares L; Geijtenbeek TB; Moris A; Saint-Remy JM; Kazatchkine MD; Kaveri SV; Lacroix-Desmazes S
Proc Natl Acad Sci U S A; 2007 May; 104(21):8965-70. PubMed ID: 17502612
[TBL] [Abstract][Full Text] [Related]
11. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.
Nogami K; Shima M; Giddings JC; Takeyama M; Tanaka I; Yoshioka A
Int J Hematol; 2007 May; 85(4):317-22. PubMed ID: 17483075
[TBL] [Abstract][Full Text] [Related]
12. Characterization of factor VIII inhibitors.
Shima M
Int J Hematol; 2006 Feb; 83(2):109-18. PubMed ID: 16513528
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII structure and function.
Fay PJ
Int J Hematol; 2006 Feb; 83(2):103-8. PubMed ID: 16513527
[TBL] [Abstract][Full Text] [Related]
14. Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.
Ori J; Tanaka I; Kubota Y; Shima M; Matsumoto T; Yoshida K; Sakurai Y; Yoshioka A
Int J Hematol; 2005 Nov; 82(4):351-6. PubMed ID: 16298830
[TBL] [Abstract][Full Text] [Related]
15. A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation.
Nogami K; Shima M; Nishiya K; Hosokawa K; Saenko EL; Sakurai Y; Shibata M; Suzuki H; Tanaka I; Yoshioka A
Blood; 2002 Jun; 99(11):3993-8. PubMed ID: 12010799
[TBL] [Abstract][Full Text] [Related]
16. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
[TBL] [Abstract][Full Text] [Related]
17. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1995 Jun; 270(23):13826-33. PubMed ID: 7775440
[TBL] [Abstract][Full Text] [Related]
18. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
Saenko EL; Shima M; Gilbert GE; Scandella D
J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
[TBL] [Abstract][Full Text] [Related]
19. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
